Haleon PLC Advances Share Buyback Program with Significant Purchase

The latest update is out from Haleon PLC ( (GB:HLN) ).

Haleon PLC announced the purchase of 1,996,340 ordinary shares as part of the second tranche of its share buyback program. The purchased shares will be held as treasury shares, impacting the company’s total share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes major categories such as Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its long-standing brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are built on trusted science and innovation.

Average Trading Volume: 20,426,806

Technical Sentiment Signal: Sell

Current Market Cap: £29.41B

For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.